A MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。一项多中心、双盲、安慰剂对照、平行分组研究设计，旨在评估左乙拉西坦(1000毫克/天，在经前增加剂量至3000毫克/天)辅助治疗成年女性受试者(18-40岁)部分发作的安全性和有效性。C1型月经性癫痫是指患有癫痫的妇女，与排卵周期的滤泡期和黄体期相比，她们在月经期的每日平均癫痫发作频率增加。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A multi-center, double-blind, placebo-controlled, parallel-group study design to assess the safety and efficacy of Levetiracetem (1000 mg/day with increased dosing during the premenstrual period to 3000 mg/day) in the adjunctive treatment of adult female subjects (18-40 years of age) with partial onset seizures, which is catamenially exacerbated in a C1 pattern. Catamenial epilepsy of C1 type are women with epilepsy who experience an increased daily average seizure frequency during the menstrual phase in comparison to the follicular and luteal phase of the ovulatory cycle.